Clinical Trials Browser

Phase 1 × GRN163L peptide × Lymphoid × Clear all

NCT00124189 2015-12-24

Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell